These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21077340)

  • 21. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Diabetic nephropathy].
    Haneda M
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():260-9. PubMed ID: 12430239
    [No Abstract]   [Full Text] [Related]  

  • 23. FPIN's clinical inquiries. Angiotensin blockade in patients with diabetic nephropathy.
    Jimenez J; Safranek S; Viera AJ
    Am Fam Physician; 2007 Aug; 76(3):423-4. PubMed ID: 17708144
    [No Abstract]   [Full Text] [Related]  

  • 24. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
    Wittmann I; Degrell P; Komáromy A; Molnár GA; Wagner Z; Wagner L; Mazák I; Nagy J
    Orv Hetil; 2003 Mar; 144(13):613-9. PubMed ID: 12728786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kidney disease in diabetology: lessons from 2008.
    Schernthaner G
    Nephrol Dial Transplant; 2009 Feb; 24(2):396-9. PubMed ID: 19144896
    [No Abstract]   [Full Text] [Related]  

  • 26. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Rossing P; Parving HH; de Zeeuw D
    Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators.
    Lai HM; Aronow WS; Kruger A; Desai H; Amin H; Frishman WH; Cohen M; Sorbera C
    Am J Cardiol; 2008 Jul; 102(1):77-8. PubMed ID: 18572039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New findings with RAS inhibitors in diabetic nephropathy].
    Ito S
    Nihon Jinzo Gakkai Shi; 2007; 49(5):485-90. PubMed ID: 17695809
    [No Abstract]   [Full Text] [Related]  

  • 30. Diabetic nephropathy.
    Castellino P; Tuttle KR; DeFronzo RA
    Curr Ther Endocrinol Metab; 1994; 5():426-36. PubMed ID: 7704768
    [No Abstract]   [Full Text] [Related]  

  • 31. [RAS blockade in diabetic nephropathy. "Early intervention can dramatically decrease loss of function].
    Ritz E
    MMW Fortschr Med; 2004 Sep; 146(38):12. PubMed ID: 15532423
    [No Abstract]   [Full Text] [Related]  

  • 32. [Prevention and remission of diabetic nephropathy].
    Sugimoto T; Nakamura Y; Makino H
    Nihon Rinsho; 2003 Jul; 61(7):1167-71. PubMed ID: 12877079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diabetes and hypertension].
    Sayk F; Iwen KA; Lehnert H
    Dtsch Med Wochenschr; 2009 Nov; 134(45):2296-301. PubMed ID: 19876807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating diabetic nephropathy: unfinished success is not failure.
    Lewis J
    Clin J Am Soc Nephrol; 2007 May; 2(3):407-9. PubMed ID: 17699442
    [No Abstract]   [Full Text] [Related]  

  • 35. Controversies on the prevention of diabetic nephropathy.
    Chiarelli F; Verrotti A; Basciani F; di Ricco L; Sabatino G; Morgese G
    J Pediatr Endocrinol Metab; 1998 Apr; 11 Suppl 2():365-9. PubMed ID: 9642666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should angiotensin II receptor blockers and statins be combined?
    Nickenig G
    Circulation; 2004 Aug; 110(8):1013-20. PubMed ID: 15326080
    [No Abstract]   [Full Text] [Related]  

  • 37. ARBs vs ACE inhibitors for preventing diabetic nephropathy.
    Greenwood V
    J Fam Pract; 2005 May; 54(5):453; discussion 453-4. PubMed ID: 15865904
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
    Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Etiology and therapy of diabetic nephropathy].
    Kikkawa R
    Nihon Naika Gakkai Zasshi; 1998 Jul; 87(7):1287-91. PubMed ID: 9745277
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiangiogenic therapy in diabetic nephropathy.
    Zent R; Pozzi A
    J Am Soc Nephrol; 2006 Feb; 17(2):325-7. PubMed ID: 16434503
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.